Evidence map›Paper›PMID 32132191›Full record

ArticleJournal of clinical microbiology2020

Direct Determination of Pyrazinamide (PZA) Susceptibility by Sputum Microscopic Observation Drug Susceptibility (MODS) Culture at Neutral pH: the MODS-PZA Assay.

Roberto Alcántara, Patricia Fuentes, Lisette Marin, Daniela E Kirwan, Robert H Gilman, Mirko Zimic, Patricia Sheen

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Phenotypic and genotypic characterization ofFrontiers in microbiology · 2024
    Article
  3. Article
  4. QuantitativeJournal of clinical microbiology · 2023
    Article
  5. Article
  6. Clinically encountered growth phenotypes of tuberculosis-causing bacilli and theirFrontiers in cellular and infection microbiology · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Roberto AlcántaraLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú roberto.alcantara@alumni-upch.edu.pe patricia.sheen@upch.pe.
Patricia FuentesLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú.
Lisette MarinLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú.
Daniela E KirwanInfection and Immunity Research Institute, St George's, University of London, London, United Kingdom.
Robert H GilmanDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Mirko ZimicLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú.
Patricia SheenLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú roberto.alcantara@alumni-upch.edu.pe patricia.sheen@upch.pe.
Universidad Peruana Cayetano Heredia · PEJohns Hopkins University · USSt George's, University of London · GB

Funding

Medical Research Council MR/P019978/1Medical Research Council MR/P019978/2Wellcome TrustWellcome Trust 099805/Z/112/Z
6 · The paper itself

Abstract

Pyrazinamide (PZA) is considered the pivot drug in all tuberculosis treatment regimens due to its particular action on the persistent forms of

Indexed as

Mycobacterium tuberculosisPharmaceutical PreparationsTuberculosis, Multidrug-ResistantAmidohydrolasesAntitubercular AgentsHumansHydrogen-Ion ConcentrationMicrobial Sensitivity TestsMutationPyrazinamideSputumAmidohydrolasesAntitubercular AgentsPharmaceutical PreparationsPyrazinamidedrug susceptibilityMODSpyrazinamidesputumtuberculosis

Identifiers

PMID32132191
PMCPMC7180241
OpenAlexW3010329081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.